General
Preferred name
LENALIDOMIDE
Synonyms
3-(4-Amino-1-oxo-1,3-dihydro-2h-isoindol-2-yl)piperidine-2,6-dione ()
CC-5013 hydrochloride ()
Lenalidomide (hydrochloride) ()
CC-5013 ()
Revlimid ()
CC5013 ()
Lenalidomide (CC-5013) ()
3-(7-Amino-3-oxo-1H-isoindol-2-yl)-piperidine-2,6-dione ()
2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)- ()
Lenalidomide (hemihydrate) ()
ENMD-0997 ()
CC-5013 hemihydrate ()
Lenalidomide hemihydrate ()
Lenalidomide hydrochloride ()
SYP-1512 ()
CDC-501 ()
NSC-747972 ()
Lenalidomide-d5 ()
P&D ID
PD004118
CAS
191732-72-6
443912-14-9
1243329-97-6
847871-99-2
1227162-34-6
Tags
PROTAC
natural product
drug
available
Approved by
PMDA
EMA
FDA
First approval
2005
Drug Status
approved
Drug indication
Multiple myeloma
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
HALF-LIFE Healthy subjects = 3 hours;; Multiple myeloma or MDS patients = 3 - 5 hours.
DESCRIPTION Lenalidomide is a derivative of with anti-inflammatory and anti-cancer actions. (GtoPdb)
DESCRIPTION Potent pan Pim kinase inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Lenalidomide is a TNF-α secretion inhibitor. (BOC Sciences Bioactive Compounds)
DESCRIPTION Lenalidomideis a derivative of thalidomide introduced in 2004. Lenalidomide (Revlimid, CC-5013) is a TNF-α secretion inhibitor with IC50 of 13 nM. (BOC Sciences Bioactive Compounds)
Cell lines
131
Organisms
1
Compound Sets
27
AdooQ Bioactive Compound Library
A10522
Axon Medchem Screening Library
1793
BOC Sciences Bioactive Compounds
lenalidomide-hemihydrate-cas-847871-99-2-item-84-463648
lenalidomide-hydrochloride-cas-1243329-97-6-item-84-463148
Cayman Chemical Bioactives
14643
22370
ChEMBL Approved Drugs
CHEMBL848
ChEMBL Drugs
CHEMBL848
DrugBank
DB00480
DrugBank Approved Drugs
DB00480
DrugCentral
3317
DrugCentral Approved Drugs
3317
DrugMAP
DM6Q7U4
DrugMAP Approved Drugs
DM6Q7U4
Enamine BioReference Compounds
Guide to Pharmacology
7331
LINCS compound set
10418-101
MedChem Express Bioactive Compound Library
HY-A0003
HY-A0003B
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
F0P408N6V4
NIH Approved Oncology Drugs
91148448
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
ReFrame library
Selleckchem Bioactive Compound Library
lenalidomide-s1029
TargetMol Bioactive Compound Library
T1642
The Spectrum Collection
Tocris Bioactive Compound Library
6305
Welcome Trust Cancer Drugs
1020
External IDs
61
Properties
(calculated by RDKit )
Molecular Weight
259.1
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
1
Ring Count
3
Aromatic Ring Count
1
cLogP
0.03
TPSA
92.5
Fraction CSP3
0.31
Chiral centers
1.0
Largest ring
6.0
QED
0.55
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
TNF alpha
Ligand for E3 Ligase
TNF-??
TNF Receptor
TNFa inhibitor
Ligands for E3 Ligase
Molecular Glues
Apoptosis related,Caspase,E3 Ligase ,E3 ligase Ligand,TNF-alpha,VEGFR
Pathway
Apoptosis
Primary Target
Ubiquitin E3 Ligases
MOA
TNF
DDB1-CRBN modulator
Angiogenesis Inhibitors
TNF-alpha Production Inhibitors
Member status
member
Therapeutic Indication
Myelodysplasia
Therapeutic Class
Anticancer
Anticancer Agents
Source data